...
首页> 外文期刊>RSC Advances >Development of nordihydroguaiaretic acid derivatives as potential multidrug-resistant selective agents for cancer treatment
【24h】

Development of nordihydroguaiaretic acid derivatives as potential multidrug-resistant selective agents for cancer treatment

机译:开发去氢双氢愈创木酸衍生物作为潜在的耐多药癌症治疗药物

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

In this research, we designed and synthesized a new series of nordihydroguaiaretic acid (NDGA) derivatives for multidrug resistance (MDR) research. A methylsulfonyl NDGA derivative, ((2R,3S)-2,3-dimethylbutane-1,4-diyl)bis(benzene-4,1,2-triyl) tetramethanesulfonate (5d), was found to inhibit MDR1 gene expression and suppress drug resistantMES-SA/Dx5 cells. Moreover, the combination of 5d and doxorubicin/terameprocol (M4N) showed a profound synergistic effect on inhibition of drug resistant cancer cells, suggesting that 5d is a potential adjuvant applied with doxorubicin or terameprocol in cancer treatment.
机译:在这项研究中,我们设计并合成了一系列新的去甲二氢愈创木酸(NDGA)衍生物用于多药耐药性(MDR)研究。发现甲基磺酰基NDGA衍生物((2R,3S)-2,3-二甲基丁烷-1,4-二基)双(苯-4,1,2-三基)四甲磺酸盐(5d)抑制MDR1基因表达并抑制耐药性MES-SA / Dx5细胞。此外,5d与阿霉素/丁氨茶酚(M4N)的组合显示出对抑制耐药性癌细胞具有深远的协同作用,这表明5d是与阿霉素或terameprocol一起用于癌症治疗的潜在佐剂。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号